Tenax Therapeutics Q2 FY26 net loss widens to $17.8 million; R&D expenses more than doubled to $12.9 million - TENX News | RalliesTenax Therapeutics Q2 FY26 net loss widens to $17.8 million; R&D expenses more than doubled to $12.9 million
T
TENX• Second-quarter results and cash position
- Tenax Therapeutics posted a Q2 net loss that widened to $17.8 million from $10.9 million a year earlier.
- R&D expense more than doubled to $12.9 million, driven by higher Phase 3 costs for LEVEL and LEVEL-2.
- Cash and equivalents rose to $118 million; $13.4 million of warrant exercises extended the cash runway into Q2 2028.
- Topline data from the Phase 3 LEVEL trial are expected in August 2026, with results slated for a late-breaking session at ESC Congress 2026.
OPY
•
